查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108116

PSMA靶向放射性核種藥物複合物市場分析及預測（至2035年）：類型、產品、技術、應用、製程、部署、最終用戶、功能

Targeted PSMA Radionuclide Drug Conjugates Market Analysis and Forecast to 2035: Type, Product, Technology, Application, Process, Deployment, End User, Functionality
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球標靶攝護腺特異性膜抗原放射性核種藥物（PSMA）市場預計將從2025年的21億美元成長到2035年的43億美元，複合年成長率（CAGR）為7.2%。 標靶攝護腺特異性膜抗原放射性核種藥物市場呈現中等集中度結構，前三大公司佔了約70%的市場。主要細分市場為攝護腺癌治療，約佔45%，其次是診斷應用，約佔25%。此市場成長的主要驅動力是前列腺癌發病率的上升和標靶治療的進步。銷售分析表明，新藥上市和治療的數量正在增加，尤其是在醫療基礎設施完善的北美和歐洲地區。

依應用領域分類，標靶攝護腺特異性膜抗原放射性核種藥物市場可分為前列腺癌治療、轉移性癌症檢測、治療診斷學及其他領域。其中，預計到2025年，前列腺癌治療領域將佔最大的市場佔有率。這一主導地位歸因於全球前列腺癌發病率的不斷上升，以及PSMA靶向放射性藥物療法作為進行性和轉移性前列腺癌有效治療手段的日益普及。這些療法能夠選擇性地針對表達PSMA的癌細胞，從而實現精準的放射治療，同時減少對周圍健康組織的傷害。臨床證據的累積、法規核准的增加以及對放射性藥物研發投資的擴大，都進一步推動了PSMA標靶治療在前列腺癌治療中的應用。

市場區隔
類型 小分子複合物、抗體複合物、胜肽複合物及其他
產品 治療藥物、診斷藥物、伴隨用藥及其他藥物。
科技 放射性同位素標記、連接子技術、標靶配體及其他
目的 前列腺癌的治療、轉移性癌症的檢測、治療診斷學等。
流程 合成、純化、品管及其他
發展 內部生產、契約製造及其他
最終用戶 醫院、癌症研究機構、專科診所、診斷實驗室及其他
功能 標靶遞送、放射線治療、影像學及其他

從功能角度來看，標靶攝護腺特異性膜抗原放射性核種藥物市場可細分為標靶遞送、放射治療、影像學及其他應用。其中，專注於治療診斷學的「放射治療」功能部門預計將在預測期內實現最快成長。這一快速成長的驅動力在於，人們對將精準診斷與標靶治療性介入結合的個人化癌症治療方案的需求日益成長。 標靶攝護腺特異性膜抗原放射性核種藥物能夠實現腫瘤的即時可視化，隨後進行標靶放射治療，從而改善治療方案的選擇和監測。放射性核素技術的進步、α和BETA發射體的日益普及以及精準腫瘤學方法的廣泛應用，預計將加速PSMA靶向放射性核素藥物偶聯物市場中放射治療應用的成長。

區域概覽

到2025年，北美將佔PSMA靶向放射性核素藥物偶聯物市場最大的佔有率，這得益於其先進的腫瘤學基礎設施、對精準醫療的積極應用以及完善的核醫學設施。該地區受益於前列腺癌的高發病率、對放射性藥物研發的大量投資，以及許多領先的生物技術和製藥公司致力於開發標靶放射性藥物療法。有利的保險報銷方案、活性化的臨床試驗活動以及創新癌症療法的早期應用進一步推動了市場成長。分子影像和治療診斷學（整合治療和診斷技術）應用領域的持續進步，進一步鞏固了北美在該市場的主導地位。

預計亞太地區將在預測期內實現最快成長，這主要得益於人們對前列腺癌的認知不斷提高、核醫學醫療基礎設施的改善以及對先進癌症治療投入的增加。中國、日本、韓國和澳洲等國家正透過政府醫療政策和私部門投資，擴大精準診斷和標靶癌症治療的覆蓋範圍。研究合作的加強、監管流程的完善以及PET成像設施的普及，正在加速該地區PET技術的普及應用。醫療保健支出的成長以及人們對個人化癌症治療日益成長的興趣，預計將推動亞太地區市場實現顯著成長。

主要趨勢和促進因素

前列腺癌發生率上升以及對標靶治療的需求增加

全球前列腺癌發生率的不斷上升是PSMA靶向放射性核素藥物偶聯物市場的主要驅動力。對能夠選擇性殺傷癌細胞並最大限度減少對健康組織損傷的高精度標靶治療療法的需求日益成長，推動了PSMA靶向放射性藥物的應用。這些療法能夠提高進行性或轉移性前列腺癌患者的治療精準度和臨床療效。隨著醫療專業人員尋求更有效的癌症治療方案，公眾意識的提高、診斷能力的拓展以及靶向放射性藥物臨床研究的持續開展，進一步促進了市場成長。

腫瘤學中治療診斷學（治療與診斷結合）方法的擴展

PSMA靶向放射性核素藥物偶聯物市場的關鍵趨勢是「診療一體化」 （治療診斷學，它將影像學和標靶治療相結合，利用同一分子標靶。醫療專業人員擴大將PSMA標靶藥物應用於疾病檢測和個人化治療方案製定，從而提高治療準確性和患者療效。放射性藥物研發、伴隨診斷和核醫技術的進步正在加速這項綜合治療方法的發展。隨著精準腫瘤學的不斷發展，治療診斷學正成為前列腺癌診斷和治療領域的變革性趨勢。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 小分子複合物
    • 抗體複合物
    • 胜肽複合物
    • 其他
  • 市場規模及預測：依產品分類
    • 治療藥物
    • 診斷藥物
    • 同時服用的藥物
    • 其他
  • 市場規模及預測：依技術分類
    • 放射性同位素標記
    • 連接技術
    • 目標配體
    • 其他
  • 市場規模及預測：依應用領域分類
    • 攝護腺癌的治療
    • 轉移性癌症的檢測
    • 治療診斷學
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 癌症研究機構
    • 專科診所
    • 診斷實驗室
    • 其他
  • 市場規模及預測：依製程分類
    • 合成
    • 純化
    • 品管
    • 其他
  • 市場規模及預測：依市場細分
    • 內部生產
    • 契約製造
    • 其他
  • 市場規模及預測：依功能分類
    • 精準投放
    • 放射線治療
    • 影像
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Novartis
  • Bayer
  • Telix Pharmaceuticals
  • Curium Pharma
  • Fusion Pharmaceuticals
  • Progenics Pharmaceuticals
  • ITM Isotope Technologies Munich
  • Endocyte
  • Lantheus Holdings
  • Advanced Accelerator Applications
  • Nordion
  • Sofie Biosciences
  • RadioMedix
  • Actinium Pharmaceuticals
  • Clarity Pharmaceuticals
  • Theragnostics
  • Alpha Tau Medical
  • NorthStar Medical Radioisotopes
  • Isotopia Molecular Imaging
  • Artios Pharma

第9章 關於我們

簡介目錄
Product Code: GIS34654

The global Targeted PSMA Radionuclide Drug Conjugates Market is projected to grow from $2.1 billion in 2025 to $4.3 billion by 2035, at a compound annual growth rate (CAGR) of 7.2%. The Targeted PSMA Radionuclide Drug Conjugates Market is characterized by a moderately consolidated structure, with the top three segments comprising approximately 70% of the market share. The leading segments include prostate cancer treatment, which holds around 45%, followed by diagnostic applications at 25%. The market is primarily driven by the increasing prevalence of prostate cancer and advancements in targeted therapy. The volume insights indicate a growing number of installations and treatments, particularly in North America and Europe, where healthcare infrastructure is more developed.

Based on Application, the Targeted PSMA Radionuclide Drug Conjugates Market is divided into Prostate Cancer Treatment, Metastatic Cancer Detection, Theranostics, and Others. Among these, the Prostate Cancer Treatment segment accounted for the largest market share in 2025. This dominance is attributed to the increasing prevalence of prostate cancer globally and the rising adoption of PSMA-targeted radionuclide therapies as an effective treatment approach for advanced and metastatic prostate cancer. These therapies enable selective targeting of PSMA-expressing cancer cells, allowing precise radiation delivery while reducing damage to surrounding healthy tissues. Growing clinical evidence supporting improved patient outcomes, increasing regulatory approvals, and rising investments in radiopharmaceutical development are further driving the adoption of targeted PSMA therapies in prostate cancer management.

Market Segmentation
TypeSmall Molecule Conjugates, Antibody Conjugates, Peptide Conjugates, Others
ProductTherapeutic Agents, Diagnostic Agents, Combination Agents, Others
TechnologyRadioisotope Labeling, Linker Technology, Targeting Ligands, Others
ApplicationProstate Cancer Treatment, Metastatic Cancer Detection, Theranostics, Others
ProcessSynthesis, Purification, Quality Control, Others
DeploymentIn-House Manufacturing, Contract Manufacturing, Others
End UserHospitals, Cancer Research Institutes, Specialty Clinics, Diagnostic Laboratories, Others
FunctionalityTargeted Delivery, Radiation Therapy, Imaging, Others

Based on Functionality, the Targeted PSMA Radionuclide Drug Conjugates Market is divided into Targeted Delivery, Radiation Therapy, Imaging, and Others. Among these, the Theranostic-focused Radiation Therapy functionality segment is projected to witness the fastest growth during the forecast period. The rapid expansion is driven by the increasing demand for personalized cancer treatment approaches that combine precise diagnosis with targeted therapeutic intervention. PSMA radionuclide drug conjugates enable real-time tumor visualization followed by targeted radiation treatment, improving treatment selection and monitoring. Advancements in radionuclide technology, growing availability of alpha and beta emitters, and increasing adoption of precision oncology approaches are expected to accelerate the growth of radiation therapy applications within the targeted PSMA radionuclide drug conjugates market.

Geographical Overview

North America accounted for the largest share of the Targeted PSMA Radionuclide Drug Conjugates Market in 2025 due to its advanced oncology infrastructure, strong adoption of precision medicine, and extensive availability of nuclear medicine facilities. The region benefits from a high prevalence of prostate cancer, significant investments in radiopharmaceutical research, and the presence of leading biotechnology and pharmaceutical companies developing targeted radionuclide therapies. Favorable reimbursement frameworks, increasing clinical trial activity, and early adoption of innovative cancer treatments further support market expansion. Continuous advancements in molecular imaging and theranostic applications continue to reinforce North America's leadership in this market.

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to rising prostate cancer awareness, improving nuclear medicine infrastructure, and increasing investments in advanced oncology care. Countries including China, Japan, South Korea, and Australia are expanding access to precision diagnostics and targeted cancer therapies through government healthcare initiatives and private sector investments. Growing research collaborations, improving regulatory pathways, and increasing availability of PET imaging facilities are accelerating regional adoption. Expanding healthcare expenditure and the growing focus on personalized cancer treatment are expected to drive significant market growth across Asia-Pacific.

Key Trends and Drivers

Rising Incidence of Prostate Cancer and Demand for Targeted Therapies:

The increasing global prevalence of prostate cancer is a major driver for the Targeted PSMA Radionuclide Drug Conjugates Market. Growing demand for highly targeted treatment approaches that selectively destroy cancer cells while minimizing damage to healthy tissues is encouraging the adoption of PSMA-targeted radionuclide therapies. These therapies offer improved treatment precision and enhanced clinical outcomes for patients with advanced or metastatic prostate cancer. Increasing awareness, expanding diagnostic capabilities, and ongoing clinical research into targeted radiopharmaceuticals are further supporting market growth as healthcare providers seek more effective oncology treatment options.

Expansion of Theranostic Approaches in Oncology:

A key trend in the Targeted PSMA Radionuclide Drug Conjugates Market is the growing adoption of theranostics, which combines diagnostic imaging and targeted therapy using the same molecular target. Healthcare providers are increasingly utilizing PSMA-targeted agents for both disease detection and personalized treatment planning, improving therapeutic precision and patient outcomes. Advances in radiopharmaceutical development, companion diagnostics, and nuclear medicine technologies are accelerating this integrated treatment approach. The continued evolution of precision oncology is positioning theranostics as a transformative trend within prostate cancer diagnosis and treatment.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Small Molecule Conjugates
    • 4.1.2 Antibody Conjugates
    • 4.1.3 Peptide Conjugates
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Agents
    • 4.2.2 Diagnostic Agents
    • 4.2.3 Combination Agents
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Radioisotope Labeling
    • 4.3.2 Linker Technology
    • 4.3.3 Targeting Ligands
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Prostate Cancer Treatment
    • 4.4.2 Metastatic Cancer Detection
    • 4.4.3 Theranostics
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Cancer Research Institutes
    • 4.5.3 Specialty Clinics
    • 4.5.4 Diagnostic Laboratories
    • 4.5.5 Others
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Synthesis
    • 4.6.2 Purification
    • 4.6.3 Quality Control
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 In-House Manufacturing
    • 4.7.2 Contract Manufacturing
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Targeted Delivery
    • 4.8.2 Radiation Therapy
    • 4.8.3 Imaging
    • 4.8.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Deployment
      • 5.2.1.8 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Deployment
      • 5.2.2.8 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Deployment
      • 5.2.3.8 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Deployment
      • 5.3.1.8 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Deployment
      • 5.3.2.8 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Deployment
      • 5.3.3.8 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Deployment
      • 5.4.1.8 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Deployment
      • 5.4.2.8 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Deployment
      • 5.4.3.8 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Deployment
      • 5.4.4.8 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Deployment
      • 5.4.5.8 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Deployment
      • 5.4.6.8 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Deployment
      • 5.4.7.8 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Deployment
      • 5.5.1.8 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Deployment
      • 5.5.2.8 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Deployment
      • 5.5.3.8 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Deployment
      • 5.5.4.8 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Deployment
      • 5.5.5.8 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Deployment
      • 5.5.6.8 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Deployment
      • 5.6.1.8 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Deployment
      • 5.6.2.8 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Deployment
      • 5.6.3.8 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Deployment
      • 5.6.4.8 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Deployment
      • 5.6.5.8 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Novartis
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Bayer
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Telix Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Curium Pharma
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Fusion Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Progenics Pharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 ITM Isotope Technologies Munich
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Endocyte
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Lantheus Holdings
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Advanced Accelerator Applications
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Nordion
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Sofie Biosciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 RadioMedix
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Actinium Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Clarity Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Theragnostics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Alpha Tau Medical
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 NorthStar Medical Radioisotopes
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Isotopia Molecular Imaging
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Artios Pharma
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us